Overview

PK and Relative Bioavailability of Novel Liquid Metformin vs Tablets

Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-28
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, three-period crossover study evaluating the single-dose pharmacokinetics and relative bioavailability of a novel liquid metformin formulation at concentrations of 100 mg/mL and 250 mg/mL compared with immediate-release metformin tablets in healthy adult subjects. All participants will receive each formulation in randomized sequence with washout periods between treatments. Serial blood samples will be collected to characterize metformin pharmacokinetic parameters, and safety and tolerability will be assessed throughout the study.
Phase:
PHASE1
Details
Lead Sponsor:
Aspargo Labs, Inc